Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tenalisib + pembrolizumab
- Development stage
- Discontinued
- Lead developer
- Rhizen Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Tenalisib + pembrolizumab is an investigational **combination therapy** evaluated in clinical trials for the treatment of relapsed or refractory classical Hodgkin lymphoma (cHL). Tenalisib is a **PI3K delta/gamma and SIK3 inhibitor** that reduces tumor-associated macrophages and angiogenesis, showing synergy with checkpoint inhibition in preclinical models. Pembrolizumab is a monoclonal antibody immune checkpoint inhibitor targeting PD-1, approved for various cancers. The combination is being tested to determine if it can overcome resistance to anti–PD-1 therapy by modulating the tumor microenvironment and enhancing immune-mediated tumor clearance[1][2][3][5][6].
- Other names
- tenalisib + KEYTRUDARP6530 + pembrolizumab
02
Targets
SIK3PDCD1 (Programmed cell death protein 1 receptor)PIK3CD (Phosphatidylinositol 3-kinase delta)PIK3CG (Phosphatidylinositol 4,5-bisphosphate 3-kinase gamma)
Beyond the preview
Go deeper on tenalisib + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tenalisib + pembrolizumab.